NCT00832650View on ClinicalTrials.gov

Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

PHASE1TerminatedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Healthy

Interventions

DRUG

fesoterodine fumarate

8 mg OD for 14 days

DRUG

placebo

OD for 14 days

DRUG

solifenacin

10 mg OD for 14 days

Trial Locations (1)

55905

Pfizer Investigational Site, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY